Implementation of advanced technologies in commercial monoclonal antibody production

Biotechnology Journal

Volumn 3, Issue 9-10, 2008, Pages 1185-1200

  Zhou, Joe X ^a   Tressel, Tim ^a   Yang, Xiaoming ^a   Seewoester, Thomas ^a  

^a AMGEN INC   (United States)

Author keywords

Commercial monoclonal antibody production; Disposable systems; Monoclonal antibodies; Process optimizations; Q'membrane chromatography

Indexed keywords

ADVANCED TECHNOLOGIES; ANTIBODY PRODUCTIONS; CELL CULTURE PROCESS; COMMERCIAL MONOCLONAL ANTIBODY PRODUCTION; COMMERCIAL PROCESS; DISPOSABLE SYSTEMS; ESSENTIAL CONSIDERATIONS; FLOW-THROUGH; HUMAN THERAPEUTIC; KEY FACTORS; MANUFACTURING COSTS; MEMBRANE ADSORBER; PACKED-BED COLUMNS; PROCESS ADVANCEMENTS; PROCESS OPTIMIZATIONS; PRODUCTION COSTS; PURIFICATION PROCESS; Q'MEMBRANE CHROMATOGRAPHY; TECHNICAL ADVANCES;

ADSORPTION; ALLERGIES; ANIMAL CELL CULTURE; CELL CULTURE; CELL MEMBRANES; CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; MEMBRANE TECHNOLOGY; MERGERS AND ACQUISITIONS; MONOCLONAL ANTIBODIES; PACKED BEDS; PROCESS CONTROL; SURFACE PLASMON RESONANCE;

THROUGHPUT;

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; XENAPAX;

AFFINITY CHROMATOGRAPHY; ANION EXCHANGE CHROMATOGRAPHY; BIOREACTOR; BIOTECHNOLOGY; CELL CULTURE; CHO CELL; DRUG IMPURITY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURITY; DRUG STABILITY; ECONOMIC ASPECT; FILTRATION; GLYCOSYLATION; ION EXCHANGE CHROMATOGRAPHY; NONHUMAN; PH; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; SUPERNATANT; VIRUS INACTIVATION; BIOSYNTHESIS; CHROMATOGRAPHY; CULTURE TECHNIQUE; INSTRUMENTATION; ISOLATION AND PURIFICATION; METHODOLOGY; PROTEIN ENGINEERING;

ANTIBODIES, MONOCLONAL; BIOREACTORS; CELL CULTURE TECHNIQUES; CHROMATOGRAPHY; CHROMATOGRAPHY, AFFINITY; PROTEIN ENGINEERING;

EID: 58749110914     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200800117     Document Type: Review

References (73)

1. Daemmrich, A., Browden, M. E., A rising drug industry. Chem. Eng. News 2005, June, 28-42.
2. Chadd, H. E., Chamow, S. M., Therapeutic antibody expression technology. Curr. Opin. Biotechnol. 2001, 12, 188-194.
3. Walsh, G., Biopharmaceuticals: Approvals and approval trends in 2004. Biopharm. Int. 2005, 18, 58-65.
4. Li, F., Zhou, J. X., Yang, X., Tressel, T., Lee, B., Current therapeutic antibody production and process optimization. Bioprocess. J. 2005, 4, 23-30.
5. Chu, L., Robinson, D. K., Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 2001, 12, 180-187.
6. Pierce, L. N., Shabram, P., Scalability of a disposable bioreactor from 25L-500L run in perfusion mode with a CHO-based cell line: A tech review. Bioprocess. J. 2004, 4, 51-56.
7. Li, F., Implementation of disposable systems in cell culture for antibody production. BioLOGIC China Conference 2007, Bei6jing, China, Sept. 4-7, 2007.
8. Gay, R., Birch, J., Approaches to improving the performance of mammalian cell cultures for protein production. BioLOGIC Conference, Boston 2004, Oct. 18-21.
9. Li, F., Pendleton, R., Lee, B., Scale-down model development and process characterization for a fed-batch cell culture process. ACS BIOT Conference, San Diego 2005, March 13-17.
10. Burky, J., Improving NS0 fed-batch culture productivity. IBC Cell Culture and Upstream Processing Conference, San Diego 2003, Dec. 8-10.
11. Fletcher, T., Designing culture media for recombinant protein production: A rational approach. Bioprocess. Int. 2005, 3, 30-36.
12. Wu, J., Le, L. C., Flynn, G., Methods for modulating mannose content of recombinant proteins, US Patent USPTO Application 20070190057, 2007.
13. Birch, J., Challenges and opportunities in large scale therapeutic protein. 19th. ESACT Meeting, Harrogate, England, 2005, June 5-8.
14. Kumar, N., Establishing process requirements for scale up of a high cell density fed-batch cell culture. AAPS conference, Boston 2006, June 22-23.
15. Kunkel, J. P., Jan, D. C. H., Jamieson, J. C., Bulter, M., Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J. Biotechnol. 1998, 62, 55-71.
16. Sauer, P. W., Burky, J. E., Wesson, M. C., Sternard, H. D., Qu, L., A high-yielding, generic fed-batch cell culture process for production of recombinant antibodies. Biotechnol. Bioeng. 2000, 67, 585-597.
17. Moore, A., Mercer, J., Dutina, G., Donahue, C. J. et al., Effects of temperature shift on cell cycle, apoptosis and nucleotide pools in CHO cell batch culture. Cytotechnology 1997, 23, 47-54.
18. Wright, A., Morrison, S. L., Effect of glycosylation on antibody function: Implications for genetic engineering. Trends Biotechnol. 1997, 15, 26-32.
19. Zhu, G. J., A high-throughput system to analyze N-glycans of NSO cell produced antibodies. IBC Cell Culture and Upstream Processing Conference, San Diego 2003, Dec. 8-10.
20. Jenkins, N., Parekh, R. B., James, D. C., Getting the glycosylation right: Implications for the biotechnology industry. Nat. Biotechnol. 1996, 14, 975-981.
21. R. Jefferis, Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 2005, 21, 11-16.
22. Leung, W. W.-F., Industrial Centrifugation Technology. McGraw-Hill, New York 1998.
23. Zhou, J. X., Tressel, T., Hong, T., Solamo, F., Dermawan, S., Development of a cost-effective, robust process for recombinant monoclonal antibody production. WilBio-Europe Antibodies & Recombinant Protein 2nd Annual Meeting, May 22-24, Amsterdam, The Netherlands 2005, May 22-24.
24. Fahrner, R. L., Whitney, D. H., Vanderlaan, M., Blank, G. S., Performance comparison of protein A affinity-chromatography sorbents for purifying recombinant monoclonal antibodies. Biotechnol. Appl. Biochem. 1999, 30, 121-128.
25. Zhou, J. X., Dehghani, H., Viral clearance: Innovative versus classical methods-theoretical & practical concerns. Am. Pharm. Rev. 2006, 14, 52-58.
26. Blank, G. S., The future of process development for Mab manufacturing. IBC's 14th International Antibody Production & Downstream Processing, March 9-11, San Diego, CA 2005.
27. Ghose, S., Hubbard, B., Cramer, S., Evaluation and comparison of alternatives to Protein A chromatography Mimetic and hydrophobic charge induction chromatographic stationary phases. J. Chromatogr. A 2006, 1122, 144-152.
28. Hart, H., Reid, K., Hart, W., Inactivation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin. Vox Sang. 1993, 64, 82-88.
29. Chin, S., Jin, R., Wang, X., Hamman, J. et al., Virucidal treatment of blood protein products with UVC radiation. Photochem. Photobiol. 1997, 65, 432-435.
30. Wang, J., Mauser, A., Chao, S.-F., Remington, K. et al., Virus inactivation and protein recovery in a noval ultraviolet-C reactor. Vox Sang. 2004, 86, 230-238.
31. Gottschalk, U., Reif, O.-W., Tarrach, K., Mora, J., Kaiser, K., An orthogonal concept for reliable virus clearance in biomanufacturing. Downstreamprocessing Technology Forum, London, UK 2004.
32. Zhou, J. X., Solamo, F., Hong, T., Shearer, M., Tressel, T., Viral clearance using disposable systems in mAb commercial downstream processing. Biotechnol. Bioeng. 2008, 100, 488-496.
33. Tipton, B., Boose, J. A., Larsen, W., Beck, J., O'Brien, T., Retrovirus and parvovirus clearance from an affinity column product using adsorptive depth filtration. BioPharm 2002, Sept., 43-50.
34. Zhou, J. X., Tressel, T., Hong, T., Li, F. et al., Optimization of antibody processing: upstream and downstream, in: Langer, E. S. (Ed.), Advances in Large Scale BioManufacturing and Scale-Up Production. ASM Press/BioPlan Associates, Inc., Rockville, MD 2007, pp. 779-816.
35. Gagnon, P., The question for a generic IgG purification procedure. WilBio-Europe, Antibodies & Recombinant Protein 2nd Annual Meeting, May 22-24, Amsterdam, The Netherlands 2005.
36. Zhou, J. X., Dermawan, S., Solamo, F., Tressel, T., Guhan, S., pH-gradient cation exchange chromatography for process-scale antibody purification. 229th ACS National Meeting, March 13-17, San Diego, CA 2005.
37. Zhou, J. X., Dermawan, S., Solamo, F., Flynn, G. et al., pH-conductivity hybride gradient cation exchange chromatography for process-scale monoclonal antibody purification. J. Cromatogr. A 2007, 1175, 69-80.
38. Franklin, S., Removal of aggregate from an IgG 4 product using CHT ceramic hydroxyapatite. Bioprocess. Int. 2003, January, 50-51.
39. Gagnon, P., Ng, P., Zhen, J., Aberin, C. et al., A ceramic hydroxyapatite based purification platform. Bioprocess. Int. 2006, 4, 50-60.
40. Yuan, Q. S., Rosenfeld, A., Root, T. W., Klingenberg, D. J., Lightfoot, E. N., Flow distribution in chromatographic columns. J. Chromatogr. A 1999, 831, 149-165.
41. Zhou, J. X., Tressel, T., Q membrane chromatography as a robust purification unit for large-scale antibody production. Bioprocess Int. 2005, 3, 32-37.
42. Zhou, J. X., Tressel, T., Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnol. Prog. 2006, 22, 341-349.
43. Bakhshayeshi-Rad, M., Zydney, A., Effect of solution pH on protein transmission and membrane capacity during virus filtration. Biotechnol. Bioeng. 2008, 100, 108-117.
44. Crane, G. A., Mittelamn, M. W., Stephan, M., Total organic carbon measurement as a substitute for the USP oxidizable substances test. J. Parenter. Sci. Technol. 1991, 45, 20-28.
45. Darling, A., Validation of biopharmaceutical purification processes for virus clearance evaluation. Mol. Biotechnol. 2002, 21, 57-83.
46. Kemp, G., O'Neil, P., Large-Scale Production of Therapeutic Antibodies: Considerations for Optimizing Product Capture and Purification. Plenum Publishers, New York 2004.
47. Martin, J., Case study-orthogonal membrane technologies for viral and DNA clearance. SCI Membrane Chromatography Conference, London, UK 2004, Nov. 3-5, http://www.soci.org/SCI/events/membrane/Martin.pdf.
48. Petsch, D., Anspach, F., Endotoxin removal from protein solutions. J. Biotechnol. 2000, 76, 97-119.
49. Knudsen, H., Fahrner, R., Xu, Y., Norling, L., Blank, G., Membrane ion-exchange chromatography for process-scale antibody purification. J. Chromatogr. A 2001, 907, 145-154.
50. Fahrner, R. L., Industrial purification of pharmaceutical antibodies: Development, operation, and validation of chromatography process. Biotechnol. Genet. Eng. Rev. 2001, 18, 301-327.
51. Brandt, S., Goffe, R. A., Kessler, S. B., O'Connor, J. L., Zale, S. E., Membrane-based affinity technology for commercial scale purifications. Biotechnology 1988, 6, 779-782.
52. Fulton, S. P., Meys, M., Varady, L., Jansen, R., Afeyan, N. B., Antibody quantitation in seconds using affinity perfusion chromatography. Biotechniques 1991, 11, 226-231.
53. Gottschalk, U., Fishcher-Fruehholz, S., A cutting edge process technology at the threshold. Bioprocess Int. 2004, May, 56-65.
54. Roper, D. K., Lightfoot, E. N., Separation of biomolecules using adsorptive membranes. J. Chromatogr. A 1995, 702, 3-26.
55. Reif, O. W., Freitag, R., Characterization and application of strong ion-exchange membrane adsorbers as stationary phases in high-performance liquid chromatography of proteins. J. Chromatogr. A 1993, 654, 29-41.
56. Lightfoot, E. N., Coffman, J. L., Lode, F., Yuan, Q. S. et al., Refining the description of protein chromatography. J. Chromatogr. A 1997, 760, 139-149.
57. Frey, D. D., Water, R. V., Zhang, B., Dispersion in stacked-membrane chromatography. J. Chromatogr. A 1992, 603, 43-47.
58. R. Ghosh, Protein separation using membrane chromatography: Opportunities and challenges. J. Chromatogr. A 2002, 952, 13-27.
59. Specht, R., Han, B., Wickramasinghe, S. R., Carlson, J. O. et al., Densonucleosis virus purification by ion exchange membranes. Biotechnol. Bioeng. 2004, 88, 465-473.
60. Kuiper, M., Sanches, R. M., Walford, J. A., Slater, N. K., Purification of a functional gene therapy vector derived from Moloney murine leukaemia virus using membrane filtration and ceramic hydroxyapatite chromatography. Biotechnol. Bioeng. 2002, 80, 445-453.
61. Teeters, M. A., Conrardy, S. E., Thomas, B. L., Root, T. W., Lightfoot, E. N., Adsorptive membrane chromatography for purification of plasmid DNA. J. Chromatogr. A 2003, 989, 165-173.
62. Zhang, S., Krivosheyeva, A., Nochumson, S., Large-scale capture and partial purification of plasmid DNA using anion-exchange membrane capsules. Biotechnol. Appl. Biochem. 2003, 37, 245-249.
63. Grunwald, A. G., Shields, M. S., Plasmid purification using membrane-based anion-exchange chromatography. Anal. Biochem. 2001, 296, 138-141.
64. Deshmukh, R. R., Warner, T. N., Hutchison, F., Murphy, M. et al., Large-scale purification of antisense oligonucleotides by high-performance membrane adsorber chromatography. J. Chromatogr. A 2000, 890, 179-192.
65. Neidhardt, E. A., Luther, M. A., Recny, M. A., Rapid, two-step purification process for the preparation of pyrogen-free murine immunoglobulin G1 monoclonal antibodies. J. Chromatogr. 1992, 590, 255-261.
66. Jungbauer, A., Unterluggauer, F., Uhl, K., Buchacher, A. et al., Scaleup of monoclonal antibody purification using radial streaming ion exchange chromatography. Biotechnol. and Bioeng. 1988, 32, 326-333.
67. Tressel, T., Zhou, J. X., Process development of an anion exchange membrane. North American Membrane Society Conference, Providence, Rhode Island, 2005, June 4-6.
68. Kubota, N., Konno, Y., Miura, S., Saito, K., Sugita, K., Comparison of two convection-aided protein adsorption methods using porous membranes and perfusion beads. Biotechnol. Prog. 1996, 12, 869-872.
69. Gerstner, J. A., Hamilton, R., Cramer, S. M., Membrane chromatographic systems for high-throughput protein separations. J. Chromatogr. A 1992, 596, 173-180.
70. Gallher, P., Fowler, E., Validation of impurity removal by the CAMPATH-1H biomanufacturing process. IBC's Biopharmaceutical Production Week, San Diego 2001, Nov. 12-15.
71. Norling, L., Lute, S., Emery, R., Khuu, W. et al., Impact of multiple re-use of anion-exchange chromatography media on virus removal. J. Chromatogr. 2005, 1069, 79-89.
72. Zhou, J. X., Tressel, T., Gottschalk, U., Solamo, F. et al., New Q membrane scale-down model for process-scale antibody purification. J. Chromatogr. A 2006, 1134, 66-73.
73. Zhang, R., Bouamama, T., Tabur, P., Zapata, G. et al., Viral clearance feasibility study with Sartobind Q membrane adsorber for human antibody purification. BioProduction 2004, http://www.sartorius.de/en/biotechnology/laboratory/ products_applications/membrane_adsorbers/literature/pdfs/ Zhang_2004_Viral_clearance_feasabiltity_study_Sartobind_Q.pdf.